

### July 2022

INSIDE

Page

# Changes to the List of Reportable Diseases, Emergency Illnesses and Health Conditions, and the List of Reportable Laboratory Findings

Beginning in May 2022, an unprecedented rapid increase in monkeypox cases has occurred in countries where the virus is not endemic and occurring in people without traditional risk factors for monkeypox virus infection. Effective July 1, 2022, pursuant to Section 19a-2a of the Connecticut General Statutes and Sections 19a-215 and 19a-36-A7 of the Regulations of Connecticut State Agencies, Manisha Juthani, MD, Commissioner of the Connecticut Department of Public Health (DPH) amended the List of Reportable Diseases, Emergency Illnesses and Health Conditions and the List of Reportable Laboratory Findings by adding monkeypox disease and orthopoxvirus and nonvariola orthopoxvirus laboratory findings to such lists. This action was taken to leverage surveillance data collection to describe the extent of the problem and use case reporting to facilitate control and response actions to reduce the spread of monkeypox.

Monkeypox disease shall be a Category 1 disease and reportable immediately by phone to DPH and the local department of health in the case patient's town of residence on the day of recognition or strong suspicion of the disease. To report, call DPH at (860) 509-7994 on weekdays or (860) 509-8000 after hours. The DPH Reportable Disease Confidential Case Report Form PD-23 shall be used to collect initial information on suspect and confirmed cases. DPH will share the report with the local health department for the town where the case patient resides and will follow up with the provider and patient as needed to collect additional information.

Currently, laboratory testing for orthopoxvirus is available through public health laboratories that are part of the Laboratory Response Network (LRN). Changes to the List of Reportable Diseases, 10 Emergency Illnesses and Health Conditions and the List of Reportable Laboratory Findings

When testing is expanded beyond the LRN, laboratories will be required to report the following laboratory findings:

- Detection of monkeypox virus (MPXV) or orthopoxvirus nucleic acid by molecular testing in a clinical specimen
- Detection of presence of orthopoxvirus by immunohistochemistry in tissue
- Detection of MPXV or orthopoxvirus by genomic sequencing in a clinical specimen
- Detection of anti-orthopoxvirus IgM antibody using a validated assay on a serum sample drawn 4-56 days after rash onset with no recent history (last 60 days) of smallpox or monkeypox vaccination

Laboratory findings should be reported immediately by phone to DPH at (860) 509-7994, followed by a fax to (860) 920-3131. DPH will provide updated instructions for electronic reporting of laboratory results once CDC guidance for such reporting is published. For information on how to report laboratory results in electronic format please email <u>DPH.InformaticsLab@ct.gov</u>.

Healthcare providers can refer questions about reporting monkeypox to the DPH Epidemiology and Emerging Infections Program at (860) 509-7994 or (860) 509-8000 after hours. Additional information on the 2022 U.S. monkeypox outbreak can be found on the Centers for Disease Control and Prevention website.

## CONTACT INFORMATION

Connecticut Department of Public Health Infectious Diseases Division 410 Capitol Avenue/MS#11FDS Hartford, CT 06134 Phone: 860-509-7995 Fax: 860-509-7910

## REPORTABLE DISEASES, EMERGENCY ILLNESSES and HEALTH CONDITIONS - 2022 PART A: REPORTABLE DISEASES

Physicians, and other professionals are required to report using the Reportable Disease Confidential Case Report form (PD-23), other disease specific form or authorized method (see page 4 for additional information). Forms can be found on the DPH <u>"Forms" webpage</u> or by calling 860-509-7994. Mailed reports must be sent in envelopes marked "CONFIDENTIAL." Changes for 2022 are in **bold font**.

<ul> <li>ategory 1 Diseases: Report immediately by telephone (860-509-7994) on the day of recognition or strong suspicion of disease for those diseases marked with a telephone (2). On evenings, weekends, and holidays call 860-509-8000. These diseases must also be reported by mail within 12 hours.</li> <li>ategory 2 Diseases: All other diseases not marked with a telephone must be reported by mail within 12 hours of recognition or strong suspicion of disease.</li> </ul>				
Acquired Immunodeficiency Syndrome (1,2)	Hepatitis C:	Powassan virus infection		
Acute flaccid myelitis	• acute infection (2)	🖀 Q fever		
Cute HIV infection	<ul> <li>perinatal infection</li> </ul>	Tabies		
Anthrax	<ul> <li>positive rapid antibody test result</li> </ul>	Ricin poisoning		
Babesiosis	HIV-1 / HIV-2 infection in: (1)	Rocky Mountain spotted fever		
Borrelia miyamotoi disease	<ul> <li>persons with active tuberculosis disease</li> </ul>	Rubella (including congenital)		
Botulism	<ul> <li>persons with a latent tuberculous</li> </ul>	Salmonellosis		
Brucellosis	infection (history or tuberculin skin test	SARS-CoV		
California group arbovirus infection	25mm induration by Mantoux	Shiga toxin-related disease (gastroenteritis		
Campylobacteriosis	technique)	Shigellosis		
Candida auris	<ul> <li>persons of any age</li> </ul>	Silicosis		
Chancroid	<ul> <li>pregnant women</li> </ul>	Smallpox		
Chickenpox	HPV: biopsy proven CIN 2, CIN 3 or AIS	St. Louis encephalitis virus infection		
Chickenpox-related death	or their equivalent (1)	Staphylococcal enterotoxin B pulmonary		
Chikungunya	Influenza-associated death (6)	poisoning		
Chlamydia (C. trachomatis) (all sites)	Influenza-associated hospitalization (6)	The staphylococcus aureus disease, reduced o		
Cholera	Legionellosis	resistant susceptibility to vancomycin (1		
Coronavirus disease 2019 (COVID-19)	Listeriosis	Staphylococcus aureus methicillin-		
COVID-19 Hospitalizations	Lyme disease	resistant disease, invasive, community		
Cryptosporidiosis	Malaria	acquired (3,9)		
Cyclosporiasis	🖀 Measles	Staphylococcus epidermidis disease,		
Dengue	🖀 Melioidosis	reduced or resistant susceptibility		
Diphtheria	Meningococcal disease	to vancomycin (1)		
E-cigarette or vaping product use	Mercury poisoning	Syphilis		
associated lung injury (EVALI)	🖀 Monkeypox disease	Tetanus		
Eastern equine encephalitis virus infection	Multisystem inflammatory syndrome in	Trichinosis		
Ehrlichia chaffeensis infection	children (MIS-C)	🖀 Tuberculosis		
Escherichia coli O157:H7 gastroenteritis	Mumps	🖀 Tularemia		
Gonorrhea	Neonatal bacterial sepsis (7)	Typhoid fever		
Group A Streptococcal disease, invasive (3)	Neonatal herpes ( $\leq 60$ days of age)	Vaccinia disease		
Group B Streptococcal disease, invasive (3)	Occupational asthma	Venezuelan equine encephalitis virus		
Haemophilus influenzae disease, invasive (3)	Toutbreaks:	infection		
Hansen's disease (Leprosy)	<ul> <li>Foodborne (involving ≥ 2 persons)</li> </ul>	Vibrio infection (parahaemolyticus,		
Healthcare-associated Infections (4)	<ul> <li>Institutional</li> </ul>	vulnificus, other)		
Hemolytic-uremic syndrome (5)	<ul> <li>Unusual disease or illness (8)</li> </ul>	Tiral hemorrhagic fever		
Hepatitis A	Pertussis	West Nile virus infection		
Hepatitis B:	The Plague	Tellow fever		
<ul> <li>acute infection (2)</li> </ul>	Pneumococcal disease, invasive (3)	Zika virus infection		
<ul> <li>HBsAg positive pregnant women</li> </ul>	The Poliomyelitis			

1. Report only to State.

- 2. As described in the CDC case definition.
- Invasive disease: from sterile fluid (blood, CSF, pericardial, pleural, peritoneal, joint, or vitreous) bone, internal body sites, or other normally sterile site including muscle.
- Report HAIs according to current CMS pay-for-reporting or pay-for-performance requirements. Detailed instructions on the types of HAIs, facility types and locations, and methods of reporting are available on the DPH website: <u>https://portal.ct.gov/ DPH/Infectious-Diseases/HAI/Healthcare-Associated-Infections-and-Antimicrobial-Resistance</u>.
- On request from the DPH and if adequate serum is available, send serum from patients with HUS to the DPH Laboratory for antibody testing.
- Submit the Hospitalized and Fatal Cases of Influenza form as specified. For influenza Hospitalizations, Electronic Medical Record access is required.
- 7. Clinical sepsis and blood or CSF isolate obtained from an infant  $\leq$  72 hours of age.
- 8. Individual cases of "significant unusual illness" are also reportable.
- Community-acquired: infection present on admission to hospital, and person has no previous hospitalizations or regular contact with the health-care setting.

How to report: The PD-23 is the general disease reporting form and should be used if other specialized forms are not available. The PD-23 can be found on the DPH "Forms" webpage (https://portal.ct.gov/DPH/Communications/Forms/Forms). It can also be ordered by writing the Department of Public Health, 410 Capitol Ave., MS#11FDS, P.O. Box 340308, Hartford, CT 06134-0308 or by calling the Epidemiology and Emerging Infections Program (860-509-7994). Specialized reporting forms are available on the DPH "Forms" webpage or by calling the following programs: Epidemiology and Emerging Infections Program (860-509-7994). Hospitalized and Fatal Cases of Influenza, Healthcare Associated Infections (860-509-7995) - National Healthcare Safety Network, HIV/AIDS Surveillance (860-509-7900) - Adult HIV Confidential Case Report form, Immunizations Program (860-509-7929) - Chickenpox Case Report (Varicella) form, Occupational Health Surveillance Program (860-509-7920), and Tuberculosis Control Program (860-509-7922). National notifiable disease case definitions are found on the CDC website.

Telephone reports of Category 1 disease should be made to the local Director of Health for the town in which the patient resides, and to the Epidemiology and Emerging Infections Program (860-509-7994). Tuberculosis cases should be directly reported to the Tuberculosis Control Program (860-509-7722). For the name, address, or telephone number of the local Director of Health for a specific town contact the Office of Local Health Administration (860-509-7660).

#### **REPORTABLE LABORATORY FINDINGS - 2022**

The director of a clinical laboratory must report laboratory evidence suggestive of reportable diseases (see page 4 for additional information). The Laboratory Report of Significant Findings form (OL-15C) can be found on the DPH <u>"Forms" webpage</u> or by calling 860-509-7994. Changes for 2022 are in **bold font**.

Anaplasma phagocytophilum by PCR only Babesia: DIFA IgM (titer) IgG (titer) 1 Other Blood smear  $\square$  PCR Unspeciated □ microti □ divergens 🗆 duncani Bordetella pertussis (titer) Culture (1) □ Non-pertussis *Bordetella* (1) (specify) DDFA D PCR Borrelia burgdorferi (2) Borrelia mivamotoi California group virus (3) spp *Campylobacter* (3) spp  $\Box$  Culture  $\Box$  PCR  $\Box$  EIA Candida auris [report samples from all sites] (1) Candida spp. [blood isolates only]: (1,3)Carbapenem-resistant Acinetobacter baumannii (CRAB) (1,4) Carbapenem-resistant Enterobacteriaceae (CRE) (1,3,4) Genus spp Carboxyhemoglobin  $\geq$  5% (2) % COHb Chikungunya virus Chlamydia trachomatis (test type) *Clostridium difficile* (5) Corynebacterium diphtheria (1) Cryptosporidium spp (3) □ PCR □ DFA □ EIA □ Microscopy □ Other:  $\square$  PCR  $\square$  Microscopy  $\square$  Other: Cyclospora spp (3) Dengue virus Eastern equine encephalitis virus *Ehrlichia chaffeensis*  $\Box$  PCR  $\Box$  IgG titers  $\geq 1:128$  only  $\Box$  Culture Enterotoxigenic Escherichia coli (ETEC) Culture PCR Escherichia coli O157(1) Culture  $\square$  PCR *Giardia* spp (3) Group A Streptococcus, invasive (1,4)  $\Box$  Culture  $\Box$  Other Group B Streptococcus, invasive (1,4) □ Culture □ Other Haemophilus ducreyi Haemophilus influenzae, invasive (1,4)  $\Box$  Culture  $\Box$  Other Hepatitis A virus (HAV): IgM anti-HAV (7) NAAT Positive (6) ALT Total Bilirubin □ Not Done Hepatitis B HBsAg Positive □ Negative (7) □ IgM anti-HBc □ HBeAg (2)  $\square$  HBV DNA (2) anti-HBs (7) Dositive (titer) □ Negative Hepatitis C virus (HCV) (8) Antibody DPCR/NAAT/RNA □ Genotype specify Herpes simplex virus (infants  $\leq 60$  days of age) Culture D PCR 🗖 IFA  $\Box$  Ag detection HIV Related Testing (report only to the State) (9)Detectable Screen (IA) Antibody Confirmation (WB/IFA/Type-diff) (9) HIV 1 □ Positive □ Neg/Ind HIV 2 Positive Neg/Ind □ HIV NAAT (or qualitative RNA) □ Detectable □ Not Detectable □ HIV Viral Load (all results) (9) \_ copies/mL □ HIV genotype (9)  $\Box$  CD4 count: cells/uL; % (9) HPV (report only to the State) (10) Biopsy proven  $\Box$  CIN 2  $\Box$  CIN 3  $\Box$  AIS or their equivalent, (specify) Type Unknown □ Type A □ Type B □ Subtype Lead poisoning (blood lead  $\ge 10 \,\mu\text{g/dL} < 48 \,\text{hrs}; 0.9 \,\mu\text{g/dL} \,\text{monthly}$ ) (11) µg/dL □ Venous level µg/dL □ Finger stick level Legionella spp (1) D DFA □ Ag positive □ Culture □ Four-fold serologic change (titers) *Listeria monocytogenes* (1) □ Culture D PCR

Mercury poisoning $\Box$ Urine $\geq 35 \ \mu g/g$ $\Box$ Blood $\geq 15 \ \mu g/g$	creatinine	μg/g	
$\Box \text{ Blood} \ge 15 \ \mu \text{g/l}$ Monkeypox virus $\Box$ Orthopoxvirus			
Non-variola orthopox	virus 🗆 PCR		•
Mumps virus (12) (	titer)		$\Box$ PCR
Mycobacterium leprae		<u> </u>	
Mycobacterium tuberci	ulosis Related Testir	ng (1)	
AFR Smear	☐ Positive □ Nega		
If positive	□ Rare □ Few	🗆 Numerou	us
ΝΔΑΤΓ	☐ Positive □ Nega	tive 🛛 Indetern	ninate
Culture [	☐ Mycobacterium tu	iberculosis	
L	☐ Non-IB mycobac	terium. (specify	М)
Neisseria gonorrhoeae			
Neisseria meningitidis,			
	Other		
Neonatal bacterial seps	18 (3,13) spp		
<i>Plasmodium</i> (1,3) spp Poliovirus			-
Powassan virus			
Rabies virus			
Rickettsia rickettsia	□ PCR □ IgG tite	ers ≥1:128 only	□ Culture
Respiratory syncytial v			
Rubella virus (12) (			
Rubeola virus (Measles			$\square$ PCR
St. Louis encephalitis v			
Salmonella (1,3)(serogr	oup & type)	Culture	$\square$ PCR
SARS-CoV (1)	□ IgM/IgG		
$\square$ PCR (spectrum)	becimen) ∐Other		
SARS-CoV2	□ PCR	□ Antigen □ Negative	
Shiga toxin (1) $\Box$ S $\Box$ PCR $\Box$ EIA		I Type Unknown	L
Shigella (1,3) (serogroup	D/spp) □ Ci	ulture 🛛 PCR	
Staphylococcus aureus	, invasive (4) $\Box$ C	ulture D Other	
□ methicillin-resist		ethicillin-sensitiv	ve
Staphylococcus aureus	, vancomycin MIC	$\geq$ 4 µg/mL (1)	
MIC to vancomycin_	μg/mL		
Staphylococcus epidern MIC to vancomycin	<i>midis</i> , vancomycin ] μg/mL	MIC $\geq$ 32 µg/mL	. (1)
Streptococcus pneumor	iiae		
$\Box$ Culture (1,4) $\Box$	<b>D</b> DT IIIe antigen	$\square$ Oulei (4)	
Treponema pallidum	$\neg$ VDRL (titer)	$ \Box$ TPPA	
Trichinella			
Varicella-zoster virus,	acute		
$\Box$ Culture $\Box$ PC	R DFA	□ Other	
Vibrio (1,3) spp	□ Culture	D PCR	
West Nile virus			
Yellow fever virus			
Yersinia, not pestis (1,3	3) spp	Culture	$\square$ PCR
Zika virus			
BIOTERRORISM at fi	rst clinical suspicior	n (14)	
Bacillus anthracis (1)		Brucella spp (1	l)
Burkholderia mallei (1)	)		oseudomallei (1)
Clostridium botulinum		Coxiella burne	tii
Francisella tularensis	antanata:- D	Ricin	1)
Staphylococcus aureus		Variola virus (	1)
Venezuelan equine enc Viral agents of hemorrh		Yersinia pestis	(1)
	-		
clude urine or sputum; for CRAE		from the DPH, send fix cimen for HPV typing.	ked tissue from the
PH, report all <i>C. difficile</i> positive	11. Report results	<u>&gt;</u> 10 μg/dL within 48 h	nours to the Local Health ad results at least monthly
Bilirubin results if conducted	to DPH only	a orn, submit ALL lea	aa results at ledst monthly

- Report peak ALT and Total Bilirubin results if conducted within one week of HAV positive test, if available. Otherwise, 12. check "Not Done".
- Negative HBsAg and all anti-HBs results only reportable for children ≤ 2 years old.
- 8. Report positive Antibody, and all RNA and Genotype results.
- Negative RNA results only reportable by electronic reporting. 9. Report all HIV antibody, antigen, viral load, and qualitative NAAT results. HIV genotype (DNA sequence) and all CD4
- vitreous), bone, internal body site (lymph node, brain, heart, liver, spleen, kidney, pancreas, or ovary), or other normally sterile site including muscle. NAAT results. HIV genotype (DNA sequence results are only reportable by electronic file

For CRE and CRAB also in

Upon request from the D

also include wounds.

stool samples.

5.

specimen.

positive results.

Specify species/serogroup/serotype.

1.

Send isolate/specimen to DPH Laboratory. Send laboratory report

(electronic or paper) on first identification of an organism. For CRE/CRAB,

antimicrobial testing. For GBS, send isolate for cases <1 year of age. For

methods, send isolate if available; send stool specimen if no isolate

available. For Shiga toxin-related disease, send positive broth or stool

Only laboratories with electronic file reporting are required to report

send laboratory report if carbapenem resistance is suggested by laboratory

Salmonella, Shigella, Vibrio, and Yersinia (not pestis) tested by non-culture

Sterile site: sterile fluids (blood, CSF, pericardial, pleural, peritoneal, joint, or

Report all IgM positive titers, only report IgG titers considered

Report all bacterial isolates from blood or CSF from infants < 72

Call the DPH, weekdays 860-509-7994; evenings, weekends.

Report positive and negative results. Electronic reporting

significant by laboratory performing the test.

hours of age.

preferred.

and holidays 860-509-8000.

14

15.

## Persons Required to Report Reportable Diseases, Emergency Illnesses and Health Conditions

- 1. Every health care provider who treats or examines any person who has or is suspected to have a reportable disease, emergency illness or health condition shall report the case to the local director of health or other health authority within whose jurisdiction the patient resides and to the Department of Public Health.
- 2. If the case or suspected case of reportable disease, emergency illness or health condition is in a health care facility, the person in charge of such facility shall ensure that reports are made to the local director of health and Department of Public Health. The person in charge shall designate appropriate infection control or record keeping personnel for this purpose.
- 3. If the case or suspected case of reportable disease, emergency illness or health condition is not in a health care facility, and if a health care provider is not in attendance or is not known to have made a report within the appropriate time, such report of reportable disease, emergency illness or health condition shall be made to the local director of health or other health authority within whose jurisdiction the patient lives and the Department of Public Health by:
  - the administrator serving a public or private school or day care center attended by any person affected or a. apparently affected with such disease, emergency illness or health condition;
  - b. the person in charge of any camp;
  - the master or any other person in charge of any vessel lying within the jurisdiction of the state; c.
  - the master or any other person in charge of any aircraft landing within the jurisdiction of the state; d.
  - the owner or person in charge of any establishment producing, handling, or processing dairy products, other food e. or non-alcoholic beverages for sale or distribution;
  - morticians and funeral directors f.

## **Persons Required to Report Reportable Laboratory Findings**

The director of a laboratory that receives a primary specimen or sample, which yields a reportable laboratory finding, shall be responsible for reporting such findings within 48 hours to the local director of health of the town in which the affected person normally resides. In the absence of such information, the reports should go to the town from which the specimen originated and to the Department of Public Health. Reports must include name, address, contact phone number, date of birth, race, ethnicity, gender, and occupation of patient.

## **IMPORTANT NOTICE**

The Reportable Disease Confidential Case Report Form PD-23 can be used to report conditions on the current list, unless there is a specialized form or other authorized method. The Laboratory Report of Significant Findings Form OL-15C can be used by staff of clinical laboratories to report evidence suggestive of reportable diseases or other approved format by DPH. Reporting forms can be found at: (https://portal.ct.gov/DPH/Communications/Forms/ Forms) or by calling 860-509-7994. Please follow these guidelines when submitting written reports:

- Forms must include name, address, and phone number of person reporting and healthcare provider, infectious agent, test method, date of onset of illness, and name, address, date of birth, race, ethnicity, gender, and occupation of patient.
- Send the white copy of completed form to DPH via fax (860-509-7910), or mail to: Connecticut Department of Public Health, 410 Capitol Ave., MS#11FDS, P.O. Box 340308, Hartford, CT 06134-0308. Mark envelope with "CONFIDENTIAL".
- Unless otherwise noted, send the vellow copy of the completed report to the Director of Health of the patient's town of residence.
- Keep the pink copy in the patient's medical record.

Connecticut Department of Public Health				
Manisha Juthani, MD		Lynn Sosa, MD		
Commissioner of Public Health		Deputy State Epidemiologist		
Infectious Diseases Programs				
Epidemiology and Emerging Infections	Healthcare Associated Infections & Antimicrobial Resistance	HIV & Viral Hepatitis		
860-509-7994	860-509-7995	860-509-7900		
Immunizations	Sexually Transmitted Diseases	Tuberculosis Control		
860-509-7929	860-509-7920	860-509-7722		
The Connecticut Epidemiologist Newsletter - (Telecommunications Relay Service 7-1-1)				

Editor: Meghan Maloney, MPH	Assistant Editor: Amanda Durante, PhD, MSc	Assistant Editor/Producer: Chris Heneghan, MPH
-----------------------------	--	--

Ε